GVS advice vericiguat (Verquvo®) for the treatment of symptomatic chronic heart failure
The National Health Care Institute has completed its assessment whether the product vericiguat (Verquvo®) can be included in the Medicine Reimbursement System (GVS). Vericiguat is indicated for the treatment of certain adult patients with symptomatic chronic heart failure with reduced ejection fraction. The National Health Care Institute advises the Minister not to include vericiguat in the GVS.
Indication for which reimbursement is requested
Vericiguat is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction that have stabilised after a recent episode of decompensation requiring intravenous treatment. The marketing authorisation holder asked for vericiguat to be included in List 1B of the Health Insurance Regulation for the registered indication.
National Health Care Institute's advice
Because no added value has been established for vericiguat added to the standard treatment for the registered indication, it does not meet the criterion of ‘established medical science and medical practice’. For that reason, the National Health Care Institute advises that vericiguat should not be included in the Medicine Reimbursement System.
The National Health Care Institute is of course prepared to reconsider the package eligibility of vericiguat if additional research data not previously assessed by the National Health Care Institute leads to scientific publications.
This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.